Breaking News

Sartorius Stedim Biotech Adds Single-Use Bioreactors

Sartorius Stedim Biotech expanded its technology portfolio with the addition of two prototypes of single-use bioreactors that operate based on novel mixing technologies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sartorius Stedim Biotech expanded its technology portfolio with the addition of two prototypes of single-use bioreactors that operate based on novel mixing technologies. These cell culture systems were developed in cooperation with the German company Bayer Technology Services GmbH (BTS) and the Swiss cell culture specialist ExcellGene SA. The new bioreactors have been designed for the manufacture of monoclonal antibodies, recombinant proteins and vaccines. The company has been offering two t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters